NAT8 and nonpapillary renal cell carcinoma: Tong et al. screened out six DEGs (including NAT8) which downregulated in ccRCC patients with VHL non-mutation than with the mutation, and its decreased expression is associated with a better prognosis in ccRCC patients [23].